Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
Portfolio Pulse from
Anixa Biosciences has initiated dosing in the third cohort of its Phase 1 clinical trial for a CAR-T therapy targeting recurrent ovarian cancer. The third cohort involves a dose of one million CAR positive cells, significantly higher than previous cohorts.
November 18, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Anixa Biosciences has dosed the first patient in the third cohort of its CAR-T therapy trial for ovarian cancer, with a significantly higher dose than previous cohorts.
The initiation of dosing in the third cohort with a higher cell count indicates progress in Anixa's clinical trial, which could lead to positive investor sentiment and a potential increase in stock price. The news is highly relevant and important as it directly pertains to the company's core business and ongoing clinical trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100